Stock Events

Stock Events

Shattuck Labs 

$6.79
12
-$0.17-2.44% Friday 20:00
-$0.10-1.47%Friday 23:55After hours

Statistics

Day High
6.81
Day Low
6.78
52W High
8.33
52W Low
1.45
Volume
35,121
Avg. Volume
-
Mkt Cap
681.47M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.42
-0.31
-0.21
-0.11
Expected EPS
-0.106858
Actual EPS
N/A

Financials

-4,880.9%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1MRevenue
-48.81MNet Income

Analyst Ratings

14.86Average Price Target
The highest estimate is 18.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow STTK. It's not an investment recommendation.
Tesla
3
TSLA
Amazon
3
AMZN
Carnival
3
CCL
Chewy
3
CHWY

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotech that competes with Shattuck Labs' focus on developing innovative immunotherapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, directly competing with Shattuck Labs in the field of genomic medicine.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing sector, making it a competitor to Shattuck Labs as both seek to harness advanced technologies for therapeutic development.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, competing with Shattuck Labs in the broader immunotherapy and cell therapy market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies for cancer, competes with Shattuck Labs in the oncology and immunotherapy space.
Novartis
NVS
Mkt Cap292.35B
Novartis, through its innovative healthcare solutions including CAR T-cell therapy Kymriah, competes in the same immunotherapy space as Shattuck Labs.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb, with a strong portfolio in immuno-oncology and cellular therapy, is a major competitor to Shattuck Labs in the development of cancer treatments.
Merck
MRK
Mkt Cap366B
Merck & Co., known for its blockbuster cancer drug Keytruda, competes with Shattuck Labs in the immunotherapy and oncology market.

About

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Show more...
CEO
Taylor H. Schreiber
Employees
40
Country
United States
ISIN
US82024L1035

Listings

XNAS
US
STTK
BOATS
BOATS
STTK.BOATS

0 Comments

Share your thoughts

FAQ

What is Shattuck Labs stock price today?▼
The current price of STTK is $6.79 USD — it has decreased by -2.44% in the past 24 hours. Watch Shattuck Labs stock price performance more closely on the chart.
What is Shattuck Labs stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Shattuck Labs stocks are traded under the ticker STTK.
Is Shattuck Labs stock price growing?▼
STTK stock has fallen by -3.55% compared to the previous week, the month change is a -7.87% fall, over the last year Shattuck Labs has showed a +338.06% increase.
What is Shattuck Labs market cap?▼
Today Shattuck Labs has the market capitalization of 681.47M
When is the next Shattuck Labs earnings date?▼
Shattuck Labs is going to release the next earnings report on November 10, 2026.
What were Shattuck Labs earnings last quarter?▼
STTK earnings for the last quarter are -0.12 USD per share, whereas the estimation was -0.12 USD resulting in a +3.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Shattuck Labs revenue for the last year?▼
Shattuck Labs revenue for the last year amounts to 1M USD.
What is Shattuck Labs net income for the last year?▼
STTK net income for the last year is -48.81M USD.
How many employees does Shattuck Labs have?▼
As of September 05, 2026, the company has 40 employees.
In which sector is Shattuck Labs located?▼
Shattuck Labs operates in the Health & Wellness sector.
When did Shattuck Labs complete a stock split?▼
The last stock split for Shattuck Labs was on December 06, 2016 with a ratio of 1:800.
Where is Shattuck Labs headquartered?▼
Shattuck Labs is headquartered in AUSTIN, United States.